From: Role of GSDMD and VEGF in differentiating between malignant and non-malignant pleural effusions
Studied variables | GSDMD | Log-rank P value | |||||
---|---|---|---|---|---|---|---|
≤ 3.51 | ˃3.51 | ||||||
Median | Std. Error | 95% CI Lower – upper | Median | Std. Error | 95% CI Lower – upper | ||
Progression-free survival | 8.00 | 3.15 | 1.82 – 14.1 | 4.00 | 0.57 | 2.86 – 14.1 | 5.15 0.023* |
Overall survival | 14.0 | 0.351 | 13.9 – 15.3 | 13.0 | 1.37 | 10.9 – 16.3 | 2.58 0.108 |
Studied variables | GSDMD | Log-rank P value | |||||
---|---|---|---|---|---|---|---|
≤ 256.4 | > 256.4 | ||||||
Median | Std. Error | 95% CI Lower – upper | Median | Std. Error | 95% CI Lower – upper | ||
Progression-free survival | 13.0 | 5.02 | 3.15 – 22.8 | 4.00 | 0.63 | 2.76 – 5.24 | 9.06 0.003* |
Overall survival | 13.0 | 0.583 | 12.9 – 15.2 | 10.0 | 1.56 | 10.6 – 16.8 | 0.843 0.359 |